{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:02:59Z","timestamp":1791424979165,"version":"4.3.3"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["807015"],"award-info":[{"award-number":["807015"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["807015"],"award-info":[{"award-number":["807015"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["807015"],"award-info":[{"award-number":["807015"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["807015"],"award-info":[{"award-number":["807015"]}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Triptans are potent 5-HT<jats:sub>1B\/1D\/1F<\/jats:sub> receptor agonists used in migraine therapy, thought to act through peripheral mechanisms. It remains unclear whether triptans cross the blood-brain barrier (BBB) sufficiently to stimulate central 5-HT<jats:sub>1B\/1D\/1F<\/jats:sub> receptors. This study investigates the disposition of eletriptan and sumatriptan in central nervous system (CNS) and peripheral nervous system (PNS) regions and predicts regional 5-HT<jats:sub>1B\/1D\/1F<\/jats:sub> receptor occupancies at clinically relevant concentrations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the Combinatory Mapping Approach (CMA) for regions of interest (ROI), we assessed the unbound tissue-to-plasma concentration ratio (K<jats:sub>p, uu, ROI<\/jats:sub>) in rats at steady state across CNS (hypothalamus, brain stem, cerebellum, frontal cortex, parietal cortex, striatum, hippocampus, whole brain, and spinal cord) and PNS (trigeminal ganglion and\u00a0sciatic nerve) regions. We used K<jats:sub>p, uu, ROI<\/jats:sub> values to estimate unbound target-site concentrations and 5-HT<jats:sub>1B\/1D\/1F<\/jats:sub> receptor occupancies in humans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We observed heterogenous triptan transport across CNS and PNS regions with the highest extent of unbound drug transport across the blood-nerve barrier in the trigeminal ganglion (K<jats:sub>p, uu, TG<\/jats:sub>: eletriptan: 0.519, and sumatriptan: 0.923). Both drugs displayed restricted entry across the BBB\u00a0(K<jats:sub>p, uu, whole brain<\/jats:sub>: eletriptan: 0.058, and sumatriptan: 0.045) combined with high inter-regional variability. We estimated near-complete receptor occupancy in the trigeminal ganglion, while lower occupancies were observed in the whole brain, irrespective of the drug or receptor subtype. For instance, eletriptan was predicted to achieve 84% 5-HT<jats:sub>1B<\/jats:sub> receptor occupancy in the trigeminal ganglion and 37% in the whole brain at clinically relevant concentrations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study suggests that despite low BBB transport, both eletriptan and sumatriptan achieve unbound concentrations sufficient to stimulate 5-HT<jats:sub>1B,<\/jats:sub> 5-HT<jats:sub>1D<\/jats:sub>, and 5-HT<jats:sub>1F<\/jats:sub> receptors not only in the trigeminal ganglion, but also in the CNS. Further research is needed to determine whether central mechanisms contribute to triptan\u2019s antimigraine effect and\/or side effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01894-0","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:52:09Z","timestamp":1730296329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Regional distribution of unbound eletriptan and sumatriptan in the CNS and PNS in rats: implications for a potential central action"],"prefix":"10.1186","volume":"25","author":[{"given":"Nana","family":"Svane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"B\u00e4llgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aghavni","family":"Ginosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birger","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Loryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"issue":"1","key":"1894_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A et al (2022) Migraine. Nat Rev Dis Primers 8(1):2","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1894_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener H-C, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Reviews Neurol 17(8):501\u2013514","journal-title":"Nat Reviews Neurol"},{"key":"1894_CR3","doi-asserted-by":"publisher","first-page":"e080107","DOI":"10.1136\/bmj-2024-080107","volume":"386","author":"WK Karlsson","year":"2024","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM et al (2024) Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ 386:e080107","journal-title":"BMJ"},{"issue":"8","key":"1894_CR4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0333102421991809","volume":"41","author":"OB Davidsson","year":"2021","unstructured":"Davidsson OB, Olofsson IA, Kogelman LJ, Andersen MA, Rostgaard K, Hjalgrim H et al (2021) Twenty-five years of triptans \u2013 a nationwide population study. Cephalalgia 41(8):894\u2013904","journal-title":"Cephalalgia"},{"key":"1894_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/JPR.S132833","volume":"11","author":"A Negro","year":"2018","unstructured":"Negro A, Koverech A, Martelletti P (2018) Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res 11:515\u2013526","journal-title":"J Pain Res"},{"issue":"1","key":"1894_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s10194-017-0811-5","volume":"18","author":"S Benemei","year":"2017","unstructured":"Benemei S, Cortese F, Labastida-Ram\u00edrez A, Marchese F, Pellesi L, Romoli M et al (2017) Triptans and CGRP blockade \u2013 impact on the cranial vasculature. J Headache Pain 18(1):103","journal-title":"J Headache Pain"},{"key":"1894_CR7","first-page":"1","volume":"21","author":"KE Cottier","year":"2017","unstructured":"Cottier KE, Vanderah TW, Largent-Milnes TM (2017) The CNS as a primary target for migraine therapeutics. Curr Top Pharmacol 21:1\u201316","journal-title":"Curr Top Pharmacol"},{"issue":"1","key":"1894_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10194-009-0170-y","volume":"11","author":"PC Tfelt-Hansen","year":"2010","unstructured":"Tfelt-Hansen PC (2010) Does Sumatriptan cross the blood-brain barrier in animals and man? J Headache Pain 11(1):5\u201312","journal-title":"J Headache Pain"},{"issue":"1\u20132","key":"1894_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pain.2005.03.008","volume":"115","author":"AH Ahn","year":"2005","unstructured":"Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115(1\u20132):1\u20134","journal-title":"Pain"},{"issue":"7","key":"1894_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","volume":"59","author":"SJ Tepper","year":"2002","unstructured":"Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B\/1D receptor agonists. Arch Neurol 59(7):1084\u20131088","journal-title":"Arch Neurol"},{"issue":"1","key":"1894_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48\u201356","journal-title":"Ann Neurol"},{"issue":"1","key":"1894_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0006-8993(01)02823-2","volume":"915","author":"K Varn\u00e4s","year":"2001","unstructured":"Varn\u00e4s K, Hall H, Bonaventure P, Sedvall G (2001) Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR 125743. Brain Res 915(1):47\u201357","journal-title":"Brain Res"},{"issue":"4","key":"1894_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0028-3908(97)00061-0","volume":"36","author":"ME Castro","year":"1997","unstructured":"Castro ME, Pascual J, Rom\u00d3N T, Del Arco C, Del Olmo E, Pazos A (1997) Differential distribution of [3H]Sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on Brainstem and spinal cord. Neuropharmacology 36(4):535\u2013542","journal-title":"Neuropharmacology"},{"key":"1894_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.brainres.2010.09.004","volume":"1361","author":"JD Classey","year":"2010","unstructured":"Classey JD, Bartsch T, Goadsby PJ (2010) Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Brain Res 1361:76\u201385","journal-title":"Brain Res"},{"issue":"1","key":"1894_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/syn.20128","volume":"56","author":"K Varn\u00e4s","year":"2005","unstructured":"Varn\u00e4s K, Hurd YL, Hall H (2005) Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse 56(1):21\u201328","journal-title":"Synapse"},{"issue":"1","key":"1894_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM (2020) Lasmiditan mechanism of action \u2013 review of a selective 5-HT1F agonist. J Headache Pain 21(1):71","journal-title":"J Headache Pain"},{"issue":"1","key":"1894_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37(1):13\u201325","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1894_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12987-024-00519-7","volume":"21","author":"Y Hu","year":"2024","unstructured":"Hu Y, Girdenyt\u00e9 M, Roest L, Liukkonen I, Siskou M, B\u00e4llgren F et al (2024) Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy. Fluids Barriers CNS 21(1):13","journal-title":"Fluids Barriers CNS"},{"issue":"6","key":"1894_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.xphs.2017.02.032","volume":"106","author":"LA Wilt","year":"2017","unstructured":"Wilt LA, Nguyen D, Roberts AG (2017) Insights into the molecular mechanism of Triptan Transport by P-glycoprotein. J Pharm Sci 106(6):1670\u20131679","journal-title":"J Pharm Sci"},{"issue":"7","key":"1894_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1124\/dmd.31.7.861","volume":"31","author":"DC Evans","year":"2003","unstructured":"Evans DC, O\u2019Connor D, Lake BG, Evers R, Allen C, Hargreaves R (2003) Eletriptan metabolism by human hepatic cyp450 enzymes and transport by human p-glycoprotein. Drug Metab Dispos 31(7):861\u20139","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1894_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1124\/jpet.102.039255","volume":"303","author":"KM Mahar Doan","year":"2002","unstructured":"Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303(3):1029\u20131037","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1894_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12987-024-00544-6","volume":"21","author":"N Svane","year":"2024","unstructured":"Svane N, Pedersen ABV, Rodenberg A, Ozg\u00fcr B, Saaby L, Bundgaard C et al (2024) The putative proton-coupled organic cation antiporter is involved in uptake of triptans into human brain capillary endothelial cells. Fluids Barriers CNS 21(1):39","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"1894_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-023-01590-5","volume":"24","author":"R Messina","year":"2023","unstructured":"Messina R, Christensen RH, Cetta I, Ashina M, Filippi M (2023) Imaging the brain and vascular reactions to headache treatments: a systematic review. J Headache Pain 24(1):58","journal-title":"J Headache Pain"},{"issue":"4","key":"1894_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/0333102419896370","volume":"40","author":"M Muzzi","year":"2019","unstructured":"Muzzi M, Zecchi R, Ranieri G, Urru M, Tofani L, De Cesaris F et al (2019) Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: implication for cluster headache treatment. Cephalalgia 40(4):330\u2013336","journal-title":"Cephalalgia"},{"issue":"9294","key":"1894_CR25","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","volume":"358","author":"MD Ferrari","year":"2001","unstructured":"Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B\/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668\u20131675","journal-title":"Lancet"},{"issue":"6","key":"1894_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1468-2982.2004.00694.x","volume":"24","author":"DW Dodick","year":"2004","unstructured":"Dodick DW, Martin V (2004) Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 24(6):417\u2013424","journal-title":"Cephalalgia"},{"issue":"3","key":"1894_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/0333102417698708","volume":"38","author":"M Deen","year":"2018","unstructured":"Deen M, Hansen HD, Hougaard A, da Cunha-Bang S, N\u00f8rgaard M, Svarer C et al (2018) Low 5-HT1B receptor binding in the migraine brain: a PET study. Cephalalgia 38(3):519\u2013527","journal-title":"Cephalalgia"},{"issue":"1","key":"1894_CR28","doi-asserted-by":"publisher","first-page":"12395","DOI":"10.1038\/s41598-023-38904-1","volume":"13","author":"LJA Kogelman","year":"2023","unstructured":"Kogelman LJA, Falkenberg K, Ottosson F, Ernst M, Russo F, Stentoft-Hansen V et al (2023) Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms. Sci Rep 13(1):12395","journal-title":"Sci Rep"},{"issue":"3","key":"1894_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1742-7843.2009.00517.x","volume":"106","author":"M Hammarlund-Udenaes","year":"2010","unstructured":"Hammarlund-Udenaes M (2010) Active-site concentrations of chemicals - are they a better predictor of effect than plasma\/organ\/tissue concentrations? Basic Clin Pharmacol Toxicol 106(3):215\u2013220","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"1894_CR30","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s11095-014-1319-1","volume":"31","author":"I Loryan","year":"2014","unstructured":"Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg W, Vermeulen A et al (2014) Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery. Pharm Res 31(8):2203\u20132219","journal-title":"Pharm Res"},{"issue":"11","key":"1894_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/mp.2015.229","volume":"21","author":"I Loryan","year":"2016","unstructured":"Loryan I, Melander E, Svensson M, Payan M, Konig F, Jansson B et al (2016) In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy. Mol Psychiatry 21(11):1527\u20131536","journal-title":"Mol Psychiatry"},{"issue":"9","key":"1894_CR32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1124\/dmd.107.015222","volume":"35","author":"M Frid\u00e9n","year":"2007","unstructured":"Frid\u00e9n M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35(9):1711\u20131719","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1894_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1124\/dmd.110.035998","volume":"39","author":"M Frid\u00e9n","year":"2011","unstructured":"Frid\u00e9n M, Bergstr\u00f6m F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M et al (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39(3):353\u2013362","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1894_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12917-020-02451-y","volume":"16","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M et al (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMC Vet Res 16(1):242","journal-title":"BMC Vet Res"},{"issue":"8","key":"1894_CR35","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","volume":"25","author":"M Hammarlund-Udenaes","year":"2008","unstructured":"Hammarlund-Udenaes M, Frid\u00e9n M, Syv\u00e4nen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25(8):1737\u20131750","journal-title":"Pharm Res"},{"issue":"7","key":"1894_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s11095-022-03246-6","volume":"39","author":"I Loryan","year":"2022","unstructured":"Loryan I, Reichel A, Feng B, Bundgaard C, Shaffer C, Kalvass C et al (2022) Unbound brain-to-plasma partition coefficient, kp,uu,brain\u2014a game changing parameter for CNS drug discovery and development. Pharm Res 39(7):1321\u20131341","journal-title":"Pharm Res"},{"issue":"1","key":"1894_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10194-010-0258-4","volume":"12","author":"A Ferrari","year":"2011","unstructured":"Ferrari A, Tiraferri I, Neri L, Sternieri E (2011) Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain 12(1):5\u201312","journal-title":"J Headache Pain"},{"key":"1894_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/DDDT.S149119","volume":"12","author":"YK Kim","year":"2018","unstructured":"Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S (2018) Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects. Drug Des Devel Ther 12:331\u2013337","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"1894_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/jcbfm.2009.200","volume":"30","author":"M Frid\u00e9n","year":"2009","unstructured":"Frid\u00e9n M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M (2009) Improved measurement of drug exposure in the Brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab 30(1):150\u2013161","journal-title":"J Cereb Blood Flow Metab"},{"issue":"8","key":"1894_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/bdd.325","volume":"23","author":"JC Kalvass","year":"2002","unstructured":"Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23(8):327\u2013338","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"1894_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-10-6","volume":"10","author":"I Loryan","year":"2013","unstructured":"Loryan I, Frid\u00e9n M, Hammarlund-Udenaes M (2013) The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS 10(1):6","journal-title":"Fluids Barriers CNS"},{"issue":"6","key":"1894_CR42","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1124\/dmd.108.026377","volume":"37","author":"M Frid\u00e9n","year":"2009","unstructured":"Frid\u00e9n M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2009) Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 37(6):1226\u20131233","journal-title":"Drug Metab Dispos"},{"key":"1894_CR43","unstructured":"DrugBank online. Eletriptan DB00216, Sumatriptan DB00669. Available from: https:\/\/go.drugbank.com\/drugs. Cited 2024, August 23rd."},{"issue":"6","key":"1894_CR44","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0731-7085(03)00245-0","volume":"32","author":"LI Bebawy","year":"2003","unstructured":"Bebawy LI, Moustafa AA, Abo-Talib NF (2003) Stability-indicating methods for the determination of sumatriptan succinate. J Pharm Biomed Anal 32(6):1123\u20131133","journal-title":"J Pharm Biomed Anal"},{"issue":"14","key":"1894_CR45","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1093\/ajhp\/54.14.1619","volume":"54","author":"DN Fish","year":"1997","unstructured":"Fish DN, Beall HD, Goodwin SD, Fox JL (1997) Stability of sumatriptan succinate in extemporaneously prepared oral liquids. Am J Health Syst Pharm 54(14):1619\u20131622","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"1894_CR46","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jpba.2009.01.034","volume":"50","author":"B Joci\u0107","year":"2009","unstructured":"Joci\u0107 B, Ze\u010devi\u0107 M, \u017divanovi\u0107 L, Proti\u0107 A, Jadranin M, Vajs V (2009) Study of forced degradation behavior of Eletriptan hydrobromide by LC and LC\u2013MS and development of stability-indicating method. J Pharm Biomed Anal 50(4):622\u2013629","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"1894_CR47","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s00216-011-5341-4","volume":"401","author":"VS Ponnuru","year":"2011","unstructured":"Ponnuru VS, Challa BR, Nadendla R (2011) Quantitative analysis of eletriptan in human plasma by HPLC-MS\/MS and its application to pharmacokinetic study. Anal Bioanal Chem 401(8):2539\u20132548","journal-title":"Anal Bioanal Chem"},{"key":"1894_CR48","first-page":"20","volume":"3","author":"N Balaji","year":"2013","unstructured":"Balaji N, Sivaraman V, Neeraja P (2013) A validated UPLC method for the determination of process-related impurities in Antimigraine bulk drug. J Appl Chem 3:20\u201328","journal-title":"J Appl Chem"},{"key":"1894_CR49","unstructured":"Kumbhar AB, Galgatte UC, Warkad SD, Santhakumari B (eds) (2013) Development and validation of a sensitive bioanalytical method for the determination of sumatriptan in rat plasma BY UPLC-MS.\u00a0https:\/\/api.semanticscholar.org\/CorpusID:41612105.\u00a0https:\/\/www.semanticscholar.org\/paper\/DEVELOPMENT-AND-VALIDATION-OF-A-SENSITIVE-METHOD-OF-Kumbhar-Galgatte\/7a6a94785124f20b1ce3ae4f8f6db4ef581bfa5e"},{"issue":"10","key":"1894_CR50","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/jms.4266","volume":"53","author":"S Udutha","year":"2018","unstructured":"Udutha S, Shankar G, Borkar RM, Kumar K, Srinivasulu G, Guntuku L et al (2018) Identification and characterization of stress degradation products of sumatriptan succinate by using LC\/Q-TOF\u2010ESI\u2010MS\/MS and NMR: toxicity evaluation of degradation products. J Mass Spectrom 53(10):963\u2013975","journal-title":"J Mass Spectrom"},{"key":"1894_CR51","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchromb.2016.02.031","volume":"1017\u20131018","author":"D Vandelli","year":"2016","unstructured":"Vandelli D, Palazzoli F, Verri P, Rustichelli C, Marchesi F, Ferrari A et al (2016) Development and validation of a liquid chromatography-tandem mass spectrometric assay for quantitative analyses of triptans in hair. J Chromatogr B 1017\u20131018:136\u2013144","journal-title":"J Chromatogr B"},{"issue":"2","key":"1894_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ph13020021","volume":"13","author":"W Wichitnithad","year":"2020","unstructured":"Wichitnithad W, Nantaphol S, Vicheantawatchai P, Kiatkumjorn T, Wangkangwan W, Rojsitthisak P (2020) Development and validation of liquid chromatography-tandem mass spectrometry method for simple analysis of sumatriptan and its application in bioequivalence study. Pharmaceuticals 13(2):21","journal-title":"Pharmaceuticals"},{"key":"1894_CR53","volume-title":"Guidance for industry: bioanalytical method validation and study sample analysis","author":"FDA","year":"2022","unstructured":"FDA (2022) Guidance for industry: bioanalytical method validation and study sample analysis"},{"issue":"1","key":"1894_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-85","volume":"15","author":"K Tokuoka","year":"2014","unstructured":"Tokuoka K, Takayanagi R, Suzuki Y, Watanabe M, Kitagawa Y, Yamada Y (2014) Theory-based analysis of clinical efficacy of triptans using receptor occupancy. J Headache Pain 15(1):85","journal-title":"J Headache Pain"},{"issue":"2","key":"1894_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0014-2999(99)00026-6","volume":"368","author":"C Napier","year":"1999","unstructured":"Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 368(2):259\u2013268","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1894_CR56","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/jpet.117.245613","volume":"365","author":"H Liu","year":"2018","unstructured":"Liu H, Chen Y, Huang L, Sun X, Fu T, Wu S et al (2018) Drug distribution into peripheral nerve. J Pharmacol Exp Ther 365(2):336\u2013345","journal-title":"J Pharmacol Exp Ther"},{"key":"1894_CR57","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/978-1-4614-9105-7_12","volume-title":"Drug delivery to the brain: physiological concepts, methodologies and approaches","author":"A Reichel","year":"2014","unstructured":"Reichel A (2014) Integrated approach to optimizing CNS penetration in drug discovery: from the Old to the new paradigm and assessment of drug\u2013transporter interactions. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG (eds) Drug delivery to the brain: physiological concepts, methodologies and approaches. Springer New York, New York, NY, pp 339\u2013374"},{"issue":"4","key":"1894_CR58","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1124\/dmd.106.012294","volume":"35","author":"JC Kalvass","year":"2007","unstructured":"Kalvass JC, Maurer TS, Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of Brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-Glycoprotein efflux ratios. Drug Metab Dispos 35(4):660\u2013666","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1894_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080634","volume":"8","author":"M Culot","year":"2013","unstructured":"Culot M, Fabulas-da Costa A, Sevin E, Szorath E, Martinsson S, Renftel M et al (2013) A simple method for assessing free brain\/free plasma ratios using an in vitro model of the blood brain barrier. PLoS ONE 8(12):e80634","journal-title":"PLoS ONE"},{"issue":"3","key":"1894_CR60","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1124\/jpet.102.039255","volume":"303","author":"KMM Doan","year":"2002","unstructured":"Doan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al (2002) Passive permeability and P-Glycoprotein-mediated efflux differentiate Central Nervous System (CNS) and Non-CNS marketed drugs. J Pharmacol Exp Ther 303(3):1029\u20131037","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1894_CR61","doi-asserted-by":"publisher","first-page":"e00575","DOI":"10.1002\/prp2.575","volume":"8","author":"C Chen","year":"2020","unstructured":"Chen C, Zhou H, Guan C, Zhang H, Li Y, Jiang X et al (2020) Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: a microdialysis study in rats. Pharmacol Res Perspect 8(2):e00575","journal-title":"Pharmacol Res Perspect"},{"issue":"7","key":"1894_CR62","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2022.06.002","volume":"34","author":"M Imbernon","year":"2022","unstructured":"Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E et al (2022) Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metabol 34(7):1054-63e7","journal-title":"Cell Metabol"},{"issue":"7","key":"1894_CR63","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2019.0755","volume":"76","author":"M Deen","year":"2019","unstructured":"Deen M, Hougaard A, Hansen HD, Schain M, Dyssegaard A, Knudsen GM et al (2019) Association between Sumatriptan treatment during a migraine attack and central 5-HT1B receptor binding. JAMA Neurol 76(7):834\u2013840","journal-title":"JAMA Neurol"},{"issue":"Suppl 1","key":"1894_CR64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1468-2982.2000.020s1002.x","volume":"20","author":"RJ Hargreaves","year":"2000","unstructured":"Hargreaves RJ (2000) Pharmacology and potential mechanisms of action of Rizatriptan. Cephalalgia 20(Suppl 1):2\u20139","journal-title":"Cephalalgia"},{"issue":"5","key":"1894_CR65","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/jcbfm.2015.19","volume":"35","author":"M Bauer","year":"2015","unstructured":"Bauer M, Karch R, Zeitlinger M, Philippe C, R\u00f6mermann K, Stanek J et al (2015) Approaching complete inhibition of P-Glycoprotein at the human blood\u2013brain barrier: an (R)-[11 C]Verapamil PET Study. J Cereb Blood Flow Metabolism 35(5):743\u2013746","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"1894_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/clpt.2011.217","volume":"91","author":"M Bauer","year":"2012","unstructured":"Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, J\u00e4ger W et al (2012) Pgp-mediated interaction between (R)-[11\u00a0C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther 91(2):227\u2013233","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1894_CR67","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1021\/acs.molpharmaceut.0c00178","volume":"17","author":"Y Uchida","year":"2020","unstructured":"Uchida Y, Yagi Y, Takao M, Tano M, Umetsu M, Hirano S et al (2020) Comparison of absolute protein abundances of transporters and receptors among blood-brain barriers at different cerebral regions and the blood-spinal cord barrier in humans and rats. Mol Pharm 17(6):2006\u20132020","journal-title":"Mol Pharm"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01894-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:54:57Z","timestamp":1730296497000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01894-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1894"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01894-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal work was conducted in accordance with the national legislations regulating animal experiments in Sweden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}